New opportunities for innovation and discovery in HIV research are within our grasp. Over the next 3 years, the National Institutes of Health will refine its science-driven HIV research enterprise to deliver the innovative, efficient results needed to turn the corner on the HIV/AIDS pandemic.
Every 7 years, NIH competitively renews its funding of the HIV clinical research networks operating in the United States and internationally. NIH is taking a proactive approach to refining the research enterprise and driving HIV discovery. By establishing a forward-looking agenda to guide this process, NIH will determine the focus and priorities of its HIV clinical trial networks through 2027. Learn more with resources available on this site and to join the conversation visit the questions and comments page.
Messages from NIAID
By Carl W. Dieffenbach, Ph.D., director, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Refining the HIV/AIDS research enterprise requires that we plan for the future. Our thinking today about the focus and priorities of the NIH HIV clinical trial networks will shape the direction of NIH clinical research through the year 2027. Planning for the next decade offers an exciting opportunity to “think big” about new opportunities for innovation and discovery. On a more granular level, this period is also an opportunity to reevaluate some of the ways in which we do business, and to ensure that processes and policies best support safety, science, and the stewardship of public funds. Read the complete blog post.
Video: Dr. Carl Dieffenbach talks about refining NIH’s HIV research enterprise
Video: Archived Presentation: Refining the Science-Driven HIV Research Enterprise